Tag:

Celgene

Latest Headlines

Latest Headlines

New Celgene meds power forward, but Revlimid's still the Big Kahuna

Celgene edged past analyst estimates for the fourth quarter and full year, with earnings of $3.71 per share and $7.67 billion in revenue for 2014. Its powerhouse remedy for multiple myeloma, Revlimid, still accounts for the lion's share of those sales, at $4.98 billion in 2014 revenue, an increase of 16%.

Celgene's Abraxane wins another OK in Europe

Celgene's Abaxane is one of those cancer fighters that has proven effective against many forms of cancer, and so the company has sought approvals far and wide, sometimes successfully and other times not. Now it has been recommended in Europe to treat lung cancer.

Eyeing an IPO, Zymeworks partners up with Celgene on bispecifics

Over the past 6 months the up-and-coming Zymeworks has leveraged its expertise in bispecific antibodies into expanded development pacts with two marquee Big Pharma partners. Later today, positioning itself for what it sees as a pivotal year, the biotech plans to announce another research deal with the prolific Big Biotech Celgene, which is inking one of its classic collaborations sweetened by an upfront payment, an equity stake and up to $164 million per project for a slate of programs that represent its biggest potential payoff yet.

JPM: Sanofi touts Toujeo prospects; Celgene eyes 22% sales hike; Valeant amps up DTC, sales hiring

When the JP Morgan Healthcare Conference rolls around, it's always a case of so much news, so little time (and space). So, we're collecting some of the bigger stories here.

NICE again thwarts Celgene's bid for Abraxane in pancreatic cancer

The U.K.'s cost-effectiveness gatekeeper is known for its stinging rejection of cancer meds, and the watchdog is singing a familiar tune with Celgene's pancreatic cancer drug Abraxane.

Celgene joins an international list of creditors in Tengion's Ch7 bankruptcy filing

Back in the summer of 2013, Celgene lined up with a group of stalwarts to pump $33 million into the struggling regenerative medicine company Tengion, which had two programs in early-stage development. Today, the biotech powerhouse was listed as a creditor on an international roster of R&D groups and support companies that are getting stiffed in a Chapter 7 filing.

Amgen vet reveals stealth startup Flexus backed by $38M from Kleiner Perkins, Celgene

After shunning public attention for more than a year, cancer immunotherapy startup Flexus Biosciences is ready for the limelight now that it is headed toward the clinic, has banked its first two venture rounds totaling $38 million and boasts impressive management, board and advisory rosters.

Amgen hopes new data can give Kyprolis a jump on rival Pomalyst

Good news for Amgen and its quest to gain a multiple myeloma edge over Celgene's Pomalyst: Results are out from a Phase III Kyprolis trial in patients with relapsed forms of the disease--and investigators say they could crown a new standard of care.

ASH Preview: Celgene, Amgen, PD-1, CD-38, Agios, Epizyme and more

Celgene will hold an investor event at the ASH conference on Dec. 7, which will doubtless provide further details on its own data and the advances of its partners.

Celgene's powerhouse Revlimid gets a little Q3 help from new friends Pomalyst, Otezla

Celgene's growth engine Revlimid came through again this quarter. The blood cancer drug's $1.3 billion in Q3 sales--a 19% increase--helped the company hit sales estimates and beat profit expectations. And if a new first-line indication wins FDA approval, expected soon, the drug could take another leap next year.